Supriya Lifescience Ltd
SUPRIYASupriya Lifescience Ltd
SUPRIYA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.72 | 7.48 | 0.11% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Supriya Lifescience is a manufacturer of pharmaceutical preparation.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 172.39 | 190.95 | 221.51 | 285.86 | 322.71 | 396.22 | 537.63 | 470.43 | 581.01 | 634.98 | ||||||||||
Raw Materials | 120.02 | 112.46 | 127.94 | 146.07 | 152.38 | 140.57 | 198.83 | 187.32 | 191.43 | 400.75 | ||||||||||
| Power & Fuel Cost | 6.64 | 6.93 | 7.03 | 0.00 | 8.97 | 9.24 | 14.07 | 20.95 | 21.37 | |||||||||||
| Employee Cost | 13.47 | 15.49 | 16.30 | 0.00 | 18.88 | 32.76 | 49.08 | 55.58 | 67.64 | |||||||||||
| Selling & Administrative Expenses | 9.53 | 8.11 | 15.85 | 0.00 | 30.10 | 31.88 | 33.83 | 37.32 | 39.43 | |||||||||||
| Operating & Other expenses | 0.67 | 23.39 | 23.84 | 67.03 | 2.92 | 3.62 | 20.25 | 30.87 | 74.48 | |||||||||||
EBITDA | 22.06 | 24.57 | 30.55 | 72.76 | 109.46 | 178.15 | 221.57 | 138.39 | 186.66 | 234.23 | ||||||||||
| Depreciation/Amortization | 3.95 | 4.75 | 5.33 | 5.44 | 6.41 | 6.76 | 10.12 | 11.82 | 15.81 | 17.27 | ||||||||||
| PBIT | 18.11 | 19.82 | 25.22 | 67.32 | 103.05 | 171.39 | 211.45 | 126.57 | 170.85 | 216.96 | ||||||||||
| Interest & Other Items | 10.04 | 11.76 | 10.75 | 10.22 | 6.85 | 4.08 | 4.20 | 3.08 | 5.15 | 1.86 | ||||||||||
| PBT | 8.07 | 8.06 | 14.47 | 57.10 | 96.20 | 167.31 | 207.25 | 123.49 | 165.70 | 215.10 | ||||||||||
| Taxes & Other Items | 2.36 | 2.40 | 5.74 | 17.68 | 22.84 | 43.71 | 55.44 | 33.63 | 46.58 | 57.61 | ||||||||||
| Net Income | 5.71 | 5.66 | 8.73 | 39.42 | 73.36 | 123.60 | 151.81 | 89.86 | 119.12 | 157.49 | ||||||||||
| EPS | 1.17 | 0.77 | 1.19 | 5.39 | 10.02 | 16.89 | 19.76 | 11.17 | 14.80 | 19.57 | ||||||||||
| DPS | 0.20 | 0.00 | 0.00 | 0.00 | 2.00 | 0.54 | 0.60 | 0.60 | 0.80 | 0.80 | ||||||||||
| Payout ratio | 0.17 | 0.00 | 0.00 | 0.00 | 0.20 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Supriya Lifescience Ltd | 51.19 | 7.48 | 0.11% |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare SUPRIYA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 16.07%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.08%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Supriya Lifescience Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
ITI Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2723% | Percentage of the fund’s portfolio invested in the stock 2.02% | Change in the portfolio weight of the stock over the last 3 months 2.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/64 (0) |
Motilal Oswal Nifty Microcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0774% | Percentage of the fund’s portfolio invested in the stock 0.27% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 96/309 (+5) |
ITI Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0762% | Percentage of the fund’s portfolio invested in the stock 1.51% | Change in the portfolio weight of the stock over the last 3 months 0.49% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 61/90 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.06 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2024
Dividend/Share
₹0.80
Ex DateEx Date
Sep 20, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Dividend/Share
₹0.60
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 1, 2022
Dividend/Share
₹0.60
Ex DateEx Date
Sep 1, 2022
Supriya Lifescience inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company's operations. This expansion boosts its Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.Powered by Capital Market - Live
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. The company said that it is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Satish Wagh, executive chairman and whole time director, Supriya Lifescience, stated, Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil. Supriya Lifesciences is primarily engaged in manufacturing of Bulk drugs and pharmaceutical chemicals. The company's standalone net profit jumped 93.3% to Rs 46.15 crore in Q2 FY25 as compared with Rs 23.88 crore in Q2 FY24. Net sales increased 18.6% YoY to Rs 166.10 crore in Q2 FY25.Powered by Capital Market - Live
Net profit of Supriya Lifescience rose 93.26% to Rs 46.15 crore in the quarter ended September 2024 as against Rs 23.88 crore during the previous quarter ended September 2023. Sales rose 18.56% to Rs 166.10 crore in the quarter ended September 2024 as against Rs 140.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales166.10140.10 19 OPM %38.9622.66 - PBDT66.8133.76 98 PBT62.0729.78 108 NP46.1523.88 93 Powered by Capital Market - Live
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
Supriya Lifesciences announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net profit of Supriya Lifescience rose 56.58% to Rs 44.64 crore in the quarter ended June 2024 as against Rs 28.51 crore during the previous quarter ended June 2023. Sales rose 21.67% to Rs 160.63 crore in the quarter ended June 2024 as against Rs 132.02 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales160.63132.02 22 OPM %38.9433.50 - PBDT64.4346.59 38 PBT59.7742.63 40 NP44.6428.51 57 Powered by Capital Market - Live
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Supriya Lifescience Aims To Double Revenue To Rs 1,000 Crore By FY27 — Know Your Company
Supriya Lifescience Q3 Review - Strong Growth Across Board On Favorable Geographical, Product Mix: DRChoksey
Supriya Lifescience shares rise post tie-up with US-based Plasma Nutrition
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.24%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.13% to 0.15%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 24.75%, vs industry avg of 15.27%